Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial);Kutane Nebenwirkungen der Kombinationstherapie mit Sorafenib und pegyliertem Interferon alfa-2b bei metastasiertem Melanom (ADO SoraPeg-Studie)

JDDG - Journal of the German Society of Dermatology

Volumn 11, Issue 9, 2013, Pages 846-853

  Degen, Annette ^a   Weichenthal, Michael ^b   Ugurel, Selma ^c,g   Trefzer, Uwe ^d   Kilian, Katharina ^e   Garbe, Claus ^f   Egberts, Friederike ^b   Poppe, Lìdia Marilia ^g   Hauschild, Axel ^b   Gutzmer, Ralf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c University Clinic for Dermatology and Venereology   (Austria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIPRURITIC AGENT; CORTICOSTEROID; METRONIDAZOLE; PEGINTERFERON ALPHA2B; SALICYLIC ACID; SORAFENIB; UREA;

ACNE; ADULT; AGED; ALOPECIA; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPITHELIUM TUMOR; FACE ERYTHEMA; FEMALE; FOLLICLE CYST; FOLLICULITIS; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LOCAL THERAPY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAMILLITIS; METASTATIC MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SEX DIFFERENCE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSIS; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSALITY; COMORBIDITY; DRUG ERUPTIONS; FEMALE; GERMANY; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84883490557     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12100     Document Type: Article

References (30)

1. Zimmer L, Vaubel J, Livingstone E, Schadendorf D,. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012; 10: 475-86.
2. Fachinformation. Nexavar Oktober 2011.
3. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-72.
4. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305.
5. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26.
6. Fachinformation. PegIntron Mai 2010.
7. Heinzerling LM, Anliker MD, Muller J, et al. Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 33: 834-9.
8. Guillot B, Blazquez L, Bessis D, et al. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004; 208: 49-54.
9. Trefzer U, Hofmann M, Sterry W,. [Cutaneous side effects of clinically relevant cytokine therapies]. Dtsch Med Wochenschr 2003; 128: 1782-7.
10. Egberts F, Gutzmer R, Ugurel S, et al. Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 2011; 22: 1667-74.
11. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288-95.
12. Ryan CW, Goldman BH, Lara PN, Jr,. et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
13. Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2011; 48: 218-25.
14. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
15. Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy-classification and management. J Dtsch Dermatol Ges 2010; 8: 652-61.
16. Perez-Soler R, Saltz L,. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining ? J Clin Oncol 2005; 23: 5235-46.
17. Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557-66.
18. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-6.
19. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-e61.
20. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7: 20-3.
21. Degen A, Satzger I, Voelker B, et al. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers ? Dermatology 2010; 221: 193-6.
22. Robert C, Arnault JP, Mateus C,. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177-82.
23. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-92.
24. Joncas V, Sammour R, Krasny M, et al. A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. Int J Dermatol 2008; 47: 767-9.
25. Wolber C, Udvardi A, Tatzreiter G, et al. Perforating folliculitis, angioedema, hand-foot syndrome-multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges 2009; 7: 449-52.
26. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.
27. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006; 42: 548-56.
28. Satzger I, Meier A, Schenck F, et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007; 121: 2562-6.
29. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
30. Bouwhuis MG, Suciu S, Collette S, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101: 869-77.